Literature DB >> 27012505

Use of cell free DNA in breast oncology.

Jenna VanLiere Canzoniero1, Ben Ho Park2.   

Abstract

Cell free DNA (cfDNA) are short fragments of nucleic acids present in circulation outside of cells. In patients with cancer, some portion of cfDNA is derived from tumor cells, termed circulating tumor DNA (ctDNA), and contains the same mutations and genetic changes as the cancer. The development of new, more effective methods to detect these changes has led to increased interest in developing ctDNA as a biomarker for cancer. Here we will review current literature on the use of ctDNA, with an emphasis on breast cancer, for cancer detection, prognosis, monitoring response to therapy, and tracking the rise of new mutant subclones.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Breast cancer; Cell free DNA; Circulating tumor DNA; Mutation

Mesh:

Substances:

Year:  2016        PMID: 27012505     DOI: 10.1016/j.bbcan.2016.03.006

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  14 in total

Review 1.  Advances in liquid biopsy using circulating tumor cells and circulating cell-free tumor DNA for detection and monitoring of breast cancer.

Authors:  Xiaofen Zhang; Shaoqing Ju; Xudong Wang; Hui Cong
Journal:  Clin Exp Med       Date:  2019-06-12       Impact factor: 3.984

Review 2.  Harnessing a Different Dependency: How to Identify and Target Androgen Receptor-Positive Versus Quadruple-Negative Breast Cancer.

Authors:  Jessica L Christenson; Jane B Trepel; Haythem Y Ali; Sunmin Lee; Joel R Eisner; Edwina S Baskin-Bey; Anthony D Elias; Jennifer K Richer
Journal:  Horm Cancer       Date:  2018-01-16       Impact factor: 3.869

3.  Somatic Tumor Mutations Detected by Targeted Next Generation Sequencing in Minute Amounts of Serum-Derived Cell-Free DNA.

Authors:  Marjolein J A Weerts; Ronald van Marion; Jean C A Helmijr; Corine M Beaufort; Niels M G Krol; Anita M A C Trapman-Jansen; Winand N M Dinjens; Stefan Sleijfer; Maurice P H M Jansen; John W M Martens
Journal:  Sci Rep       Date:  2017-05-18       Impact factor: 4.379

4.  Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages.

Authors:  Meng Yang; Umit Topaloglu; W Jeffrey Petty; Matthew Pagni; Kristie L Foley; Stefan C Grant; Mac Robinson; Rhonda L Bitting; Alexandra Thomas; Angela T Alistar; Rodwige J Desnoyers; Michael Goodman; Carol Albright; Mercedes Porosnicu; Mihaela Vatca; Shadi A Qasem; Barry DeYoung; Ville Kytola; Matti Nykter; Kexin Chen; Edward A Levine; Edgar D Staren; Ralph B D'Agostino; Robin M Petro; William Blackstock; Bayard L Powell; Edward Abraham; Boris Pasche; Wei Zhang
Journal:  J Hematol Oncol       Date:  2017-05-04       Impact factor: 17.388

Review 5.  Liquid Biopsy in Clinical Management of Breast, Lung, and Colorectal Cancer.

Authors:  Ivana Bratić Hench; Jürgen Hench; Markus Tolnay
Journal:  Front Med (Lausanne)       Date:  2018-01-30

Review 6.  Cell-free circulating tumor DNA analysis for breast cancer and its clinical utilization as a biomarker.

Authors:  Ru Wang; Xiao Li; Huimin Zhang; Ke Wang; Jianjun He
Journal:  Oncotarget       Date:  2017-09-01

7.  Circulating tumour DNA (ctDNA) as a biomarker in metachronous melanoma and colorectal cancer- a case report.

Authors:  Leslie Calapre; Lydia Warburton; Michael Millward; Elin S Gray
Journal:  BMC Cancer       Date:  2019-11-14       Impact factor: 4.430

8.  Evaluating the cerebrospinal fluid ctDNA detection by next-generation sequencing in the diagnosis of meningeal Carcinomatosis.

Authors:  Yue Zhao; Jun-Ying He; Yue-Li Zou; Xiao-Su Guo; Jun-Zhao Cui; Li Guo; Hui Bu
Journal:  BMC Neurol       Date:  2019-12-19       Impact factor: 2.474

Review 9.  Predictive value of circulating cell-free DNA in the survival of breast cancer patients: A systemic review and meta-analysis.

Authors:  Jing Yang; Li Cheng; Jing Zhang; Linyan Chen; Denian Wang; Xinli Guo; Xuelei Ma
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

10.  TP53 Mutations in Serum Circulating Cell-Free Tumor DNA As Longitudinal Biomarker for High-Grade Serous Ovarian Cancer.

Authors:  Silvia R Vitale; Floris H Groenendijk; Ronald van Marion; Corine M Beaufort; Jean C Helmijr; Hendrikus Jan Dubbink; Winand N M Dinjens; Patricia C Ewing-Graham; Ramon Smolders; Helena C van Doorn; Ingrid A Boere; Els M J J Berns; Jozien Helleman; Maurice P H M Jansen
Journal:  Biomolecules       Date:  2020-03-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.